|
|
Articles
by
K. W Kim |
Total Records (
3 ) for
K. W Kim |
|
 |
|
|
|
J. Y Choi
,
M. J Kim
,
J. Y Lee
,
J. S Lim
,
J. J Chung
,
K. W Kim
and
H. S. Yoo
|
|
OBJECTIVE. The purpose of this article is to present the typical and
atypical manifestations of serous cystadenoma, which can be visualized with
cross-sectional imaging.
CONCLUSION. Serous cystadenomas of the pancreas have various
distinguishing imaging features. Typically, a serous cystadenoma is
morphologically classified as having either a polycystic, honeycomb, or
oligocystic pattern. Atypical manifestations of serous cystadenoma can include
giant tumors with ductal dilatation, intratumoral hemorrhages, solid variants,
unilocular cystic tumors, interval growth, and a disseminated form. |
|
|
|
|
|
M. N Lee
,
S. N Lee
,
S. H Kim
,
B Kim
,
B. K Jung
,
J. H Seo
,
J. H Park
,
J. H Choi
,
S. H Yim
,
M. R Lee
,
J. G Park
,
J. Y Yoo
,
J. H Kim
,
S. T Lee
,
H. M Kim
,
S Ryeom
,
K. W Kim
and
G. T. Oh
|
|
Background
Vascular endothelial growth factor A (VEGFA), a critical mediator of tumor angiogenesis, is a well-characterized target of hypoxia-inducible factor 1 (HIF-1). Murine arrest-defective protein 1A (mARD1A225) acetylates HIF-1, triggering its degradation, and thus may play a role in decreased expression of VEGFA.
Methods
We generated ApcMin/+/mARD1A225 transgenic mice and quantified growth of intestinal polyps. Human gastric MKN74 and murine melanoma B16F10 cells overexpressing mARD1A225 were injected into mice, and tumor growth and metastasis were measured. VEGFA expression and microvessel density in tumors were assessed using immunohistochemistry. To evaluate the role of mARD1A225 acetylation of Lys532 in HIF-1, we injected B16F10-mARD1A225 cell lines stably expressing mutant HIF-1/K532R into mice and measured metastasis. All statistical tests were two-sided, and P values less than .05 were considered statistically significant.
Results
ApcMin/+/mARD1A225 transgenic mice (n = 25) had statistically significantly fewer intestinal polyps than ApcMin/+ mice (n = 21) (number of intestinal polyps per mouse: ApcMin/+ mice vs ApcMin/+/mARD1A225 transgenic mice, mean = 83.4 vs 38.0 polyps, difference = 45.4 polyps, 95% confidence interval [CI] = 41.8 to 48.6; P < .001). The growth and metastases of transplanted tumors were also statistically significantly reduced in mice injected with mARD1A225-overexpressing cells than in mice injected with control cells (P < .01). Moreover, overexpression of mARD1A225 decreased VEGFA expression and microvessel density in tumor xenografts (P < .04) and ApcMin/+ intestinal polyps (P = .001). Mutation of lysine 532 of HIF-1 in B16F10-mARD1A225 cells prevented HIF-1 degradation and inhibited the antimetastatic effect of mARD1A225 (P < .001).
Conclusion
mARD1A225 may be a novel upstream target that blocks VEGFA expression and tumor-related angiogenesis.
|
|
|
|
|
|
Y. J Park
,
J. W Yoon
,
K. I Kim
,
Y. J Lee
,
K. W Kim
,
S. H Choi
,
S Lim
,
D. J Choi
,
K. H Park
,
J. H Choh
,
H. C Jang
,
S. Y Kim
,
B. Y Cho
and
C. Lim
|
|
Background
Some studies have proposed that subclinical hypothyroidism (SCH) has adverse effects on the cardiovascular system, but little is known about the effect on patients undergoing cardiovascular operations. We examined the influence of preoperative SCH on postoperative outcome in patients undergoing coronary artery bypass grafting (CABG).
Methods
Among patients who underwent CABG between July 2005 and June 2007 at Seoul National University Bundang Hospital, 224 with normal thyroid function and 36 with SCH were enrolled. Preoperative risks and postoperative outcomes were evaluated prospectively without thyroid hormone replacement.
Results
There were no significant differences in primary outcomes (major adverse cardiovascular events) and secondary outcomes such as wound problems, mediastinitis, leg infection, respiratory complications, delirium, or reoperation during the same hospitalization. However, patients with SCH had a higher incidence of postoperative atrial fibrillation than those with normal thyroid function after adjustment for age, gender, body mass index, and other independent variables such as emergency operation, the use of cardiopulmonary bypass, combined valvular operation, preoperative creatinine levels, left ventricular systolic dysfunction, and nonuse of β-blockers (45.5% vs 29%; odds ratio, 2.552; 95% confidence interval, 1.117 to 5.830; p = 0.026).
Conclusions
SCH appears to influence the postoperative outcome for patients by increasing the development of postoperative atrial fibrillation. However, it is still unproven whether preoperative thyroxine replacement therapy for patients with SCH might prevent postoperative atrial fibrillation after CABG.
|
|
|
|
|
|
|